Brad Hauser, Chief Executive Officer of Autonomix, discusses the Company's agreement to license FDAcleared ablation technology from RF Innovations, Inc. For the segment, Brad Hauser, Chief Executive Officer of Autonomix, discussed the Company's recently announced definitive agreement with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property underlying its Apex 6 Radiofrequency Generator and what this agreement means for the Company's development program. Ab ...

For the segment, Brad Hauser, Chief Executive Officer of Autonomix, discussed the Company's recently announced definitive agreement with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property underlying its Apex 6 Radiofrequency Generator and what this agreement means for the Company's development program. We are initially developing technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pa ...

Core Viewpoint - Autonomix Medical (NASDAQ:AMIX) experienced significant stock volatility, with a notable rally followed by a decline in share price due to market reactions and company announcements [1][6]. Group 1: Stock Performance - AMIX stock rallied 130% during normal trading hours yesterday, with approximately 152 million shares traded, significantly above its daily average of about 3 million shares [5]. - Following the rally, AMIX stock is down 16.7% as of Tuesday morning, indicating a correction after the previous day's gains [6]. Group 2: Company Developments - Autonomix Medical announced a definitive agreement with RF Innovations to license the intellectual property of its Apex 6 Radiofrequency Generator, expected to be completed by the end of the month [2]. - The company provided updates on its pancreatic cancer pain management device, reporting positive results from a clinical trial that utilizes radiofrequency (RF) ablation to alleviate pain in pancreatic cancer patients [4].

Per the release, Autonomix intends to leverage the technology in its strategic therapeutic units to enhance value for its pipeline. "This transaction represents a significant step forward for the development and commercialization of our innovative technology platform and can potentially simplify our regulatory strategy, as the Apex 6 Generator is already FDA-cleared in pain management," stated President and CEO Brad Hauser. At the same time, Autonomix is a speculative enterprise. The company made its public ...

RF Innovations' Apex 6 Generator aligns with specifications required for Autonomix's ablation system and facilitates ongoing development Transaction further reinforces Autonomix's FDA regulatory pathway THE WOODLANDS, TX, July 15, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has entered ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 21 Waterway Avenue, Suite 300 The Woodlands, Texas 77380 (Address of Principal Executive Offices) (Zip Code) Registrant's Telephone Number, including Area Code: (713) 588-6150 Securities Registered Pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Nam ...

CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system Continued progress in first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer Exhibit 99.1 Topline data from first five patients in proof-of-concept (P ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to__________ Commission file number 001-41940 Autonomix Medical, Inc. (Exact Name of Registrant as Specified in Its Charter) De ...